Moody Lynn & Lieberson LLC Decreases Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Moody Lynn & Lieberson LLC cut its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 7.4% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 46,176 shares of the medical research company's stock after selling 3,674 shares during the period. Thermo Fisher Scientific comprises approximately 1.5% of Moody Lynn & Lieberson LLC's investment portfolio, making the stock its 23rd biggest position. Moody Lynn & Lieberson LLC's holdings in Thermo Fisher Scientific were worth $22,977,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of the company. One Charles Private Wealth Services LLC boosted its stake in shares of Thermo Fisher Scientific by 4.2% in the 4th quarter. One Charles Private Wealth Services LLC now owns 499 shares of the medical research company's stock valued at $260,000 after purchasing an additional 20 shares during the last quarter. Revolve Wealth Partners LLC raised its holdings in shares of Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock worth $255,000 after purchasing an additional 20 shares during the period. Holderness Investments Co. raised its holdings in Thermo Fisher Scientific by 1.7% during the 4th quarter. Holderness Investments Co. now owns 1,277 shares of the medical research company's stock valued at $664,000 after acquiring an additional 21 shares during the period. Port Capital LLC boosted its holdings in shares of Thermo Fisher Scientific by 1.6% in the fourth quarter. Port Capital LLC now owns 1,385 shares of the medical research company's stock worth $721,000 after acquiring an additional 22 shares during the period. Finally, Clark Capital Management Group Inc. raised its stake in shares of Thermo Fisher Scientific by 0.5% during the 4th quarter. Clark Capital Management Group Inc. now owns 4,445 shares of the medical research company's stock valued at $2,312,000 after purchasing an additional 23 shares during the period. 89.23% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific Stock Performance

NYSE TMO traded up $6.28 on Wednesday, reaching $427.75. 2,669,334 shares of the company's stock traded hands, compared to its average volume of 1,967,098. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $627.88. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.38 and a current ratio of 1.77. The firm has a market cap of $161.47 billion, a price-to-earnings ratio of 25.09, a P/E/G ratio of 2.16 and a beta of 0.77. The stock has a 50 day moving average price of $409.16 and a 200-day moving average price of $481.67.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating analysts' consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The company had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. During the same quarter last year, the firm posted $5.11 EPS. The firm's revenue for the quarter was up .2% on a year-over-year basis. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Friday, June 13th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 0.40%. The ex-dividend date of this dividend is Friday, June 13th. Thermo Fisher Scientific's payout ratio is currently 10.09%.

Insider Transactions at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 300 shares of the company's stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the transaction, the executive vice president directly owned 23,167 shares of the company's stock, valued at $9,960,188.31. This represents a 1.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.33% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. Royal Bank Of Canada lowered their price target on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating on the stock in a report on Thursday, April 24th. Wall Street Zen raised shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research note on Wednesday, May 21st. Scotiabank cut their price target on shares of Thermo Fisher Scientific from $650.00 to $605.00 and set a "sector perform" rating for the company in a research note on Friday, April 25th. Stifel Nicolaus lowered their price objective on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating on the stock in a research report on Thursday, April 24th. Finally, Argus reduced their price objective on Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating on the stock in a research note on Tuesday, April 29th. Four investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $604.05.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.